Health Secretary Wes Streeting expressed his gratitude for the opportunity to meet with former Little Mix member Jesy Nelson and commended her for sharing her personal journey. The meeting centered around Jesy’s plea for the implementation of newborn screening for spinal muscular atrophy (SMA), a condition affecting her twin babies that may prevent them from walking.
The Mirror is advocating for the inclusion of a simple £5 SMA check in the NHS newborn heel prick test to enable early treatment and potential cure before irreversible nerve damage occurs. Health Secretary Streeting acknowledged Jesy’s courage in discussing her family’s situation and acknowledged her potential to offer hope and comfort to other families in similar circumstances.
Emphasizing the importance of screening, Streeting highlighted ongoing efforts to enhance newborn screening for SMA. He mentioned that the UK National Screening Committee has recommended a large-scale study on this matter, with hundreds of thousands of babies soon to be screened for SMA. Streeting noted advancements in SMA treatments, leading to improved outcomes for affected children.
Jesy’s meeting with Streeting, also attended by the charity SMA UK, underscored the critical implications of delayed diagnoses. The encounter, partially filmed, will be featured on ITV’s This Morning. Novartis, a pharmaceutical company, estimated that 33 UK infants annually face wheelchair dependency due to late SMA diagnoses.
Zolgensma, a one-time gene therapy provided by Novartis through the NHS, can preserve vital motor functions in babies if administered promptly after birth. The therapy targets the genetic root cause of SMA, replacing the non-functional SMN1 gene with a functional copy.
Novartis UK’s Chief Medical Officer, Rob Hastings, urged the government to expand newborn SMA screening nationwide, aligning with standard practices in many European countries. Late-diagnosed SMA children, particularly those with severe Type 1 form, often require extensive medical support.
Jesy Nelson, a first-time mother, lamented the delayed diagnosis of her twins and emphasized the importance of early treatment for SMA. She expressed frustration over missed opportunities for intervention that could have preserved her children’s mobility. Jesy’s advocacy has sparked discussions on the need for improved screening and genomic medicine utilization in addressing SMA.
Overall, the collaborative efforts of individuals like Jesy Nelson, healthcare professionals, and advocacy groups aim to enhance early detection and treatment options for SMA, offering affected children a chance at a healthier future.